-
公开(公告)号:EP3375791A1
公开(公告)日:2018-09-19
申请号:EP18169332.6
申请日:2010-09-30
IPC分类号: C07K16/28 , A61K39/395 , A61P35/00
CPC分类号: C07K16/2818 , A61K38/1709 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2827 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要: The present invention provides agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
-
公开(公告)号:EP3362475A1
公开(公告)日:2018-08-22
申请号:EP16779112.8
申请日:2016-10-11
申请人: Innate Pharma , Centre Léon Bérard
发明人: CAUX, Christophe , GAUTHIER, Laurent , GOURDIN, Nicolas , MENETRIER-CAUX, Christine , PATUREL, Carine , PERROT, Ivan
CPC分类号: C07K16/2896 , C07K16/40 , C07K2317/33 , C07K2317/34 , C07K2317/74 , C07K2317/92
摘要: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39- expressing B cells and ATP. The disclosure also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
-
公开(公告)号:EP3349768A1
公开(公告)日:2018-07-25
申请号:EP16847105.0
申请日:2016-09-12
发明人: HAN, Kyung Ho , LERNER, Richard A.
IPC分类号: A61K35/12 , A61K35/15 , A61K49/16 , C12N5/0786
CPC分类号: A61K35/15 , A61K2039/505 , A61P37/06 , C07K16/40 , C07K2317/21 , C07K2317/622 , C07K2317/64 , C07K2317/70 , C07K2317/74 , C12N5/0645
摘要: The invention provides specific anti-Cathepsin G antibodies that are capable of inducing formation of anti-inflammatory macrophage. The invention also provides methods for generating anti-inflammatory macrophages. The methods involve contacting bone marrow cells or monocytes with a Cathepsin G antibody described herein, and culturing the cell mixture under conditions to allow formation of M2 macrophage. Also provided in the invention are therapeutic methods of using a pharmaceutical composition containing a Cathepsin G antibody or induced M2 macrophage described herein for treating autoimmune diseases and other disorders associated with undesired immune responses.
-
公开(公告)号:EP3310812A2
公开(公告)日:2018-04-25
申请号:EP16732195.9
申请日:2016-06-16
发明人: MATHIEU, Mary , DENNIS, Mark
CPC分类号: C07K16/2809 , A61K39/39558 , A61P35/00 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/73 , C07K2317/74 , C07K2317/92 , C07K2317/94
摘要: The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.
-
公开(公告)号:EP3177649A4
公开(公告)日:2018-04-25
申请号:EP15829791
申请日:2015-08-05
申请人: CB THERAPEUTICS INC
发明人: SUN ZIYONG , ZHA JIPING , QIU JUNZHUAN
CPC分类号: C07K16/2827 , A61K47/6849 , C07K2317/24 , C07K2317/565 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要: The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to PD-L1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-L1 antibodies and methods of use thereof.
-
公开(公告)号:EP3272772A1
公开(公告)日:2018-01-24
申请号:EP17189435.5
申请日:2014-07-29
发明人: Kim, Kyung Eun , Han, Sang Yeul , Koh, Gou Young , Lee, Hyo Seon , Kim, Chan
CPC分类号: C07K16/28 , A61K38/17 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2317/32 , C07K2317/565 , C07K2317/74 , C07K2317/75 , C07K2317/77 , C07K2317/92
摘要: A method of preventing or treating cancer using an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes to a Tie2 receptor while bound with Ang2.
摘要翻译: 使用特异性结合血管生成诱导因子血管生成素-2(Ang2)并与Tie2受体复合并与Ang2结合的抗Ang2抗体或其抗原结合片段预防或治疗癌症的方法。
-
公开(公告)号:EP3230319A1
公开(公告)日:2017-10-18
申请号:EP15808464.0
申请日:2015-12-02
发明人: ABDICHE, Yasmina Noubia , CHO, Helen Kim , HO, Weihsien , JOOSS, Karin Ute , RAJPAL, Arvind , YOUSSEF, Sawsan
CPC分类号: A61K39/39 , A61K39/0011 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/53 , A61K2039/545 , C07K16/2818 , C07K16/2878 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
摘要翻译: 本发明提供了与程序性细胞死亡蛋白1(PD-1)结合的拮抗性抗体及其使用方法。 抗PD-1抗体可以单独治疗或与其他治疗剂组合用于治疗癌症和其他疾病。
-
公开(公告)号:EP2814844B1
公开(公告)日:2017-08-02
申请号:EP12794962.6
申请日:2012-11-30
申请人: Novo Nordisk A/S
发明人: STENNICKE, Vibeke Westphal , READ, Christine Brender , GRELL, Susanne Nedergaard , WIBERG, Charlotte , SALBO, Rune , HENRIKSEN, Anette , PADKJÆR, Søren
IPC分类号: C07K16/28
CPC分类号: C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/74 , C07K2317/76 , C07K2317/92
-
公开(公告)号:EP2933268B1
公开(公告)日:2017-07-12
申请号:EP15151109.4
申请日:2011-08-23
发明人: Liu, Yong-Jun , Voo, Kui Shin , Bover, Laura , Tsurushita, Naoya , Tso, J. Yun , Kumar, Shankar
IPC分类号: C07K16/28 , C12N15/13 , A61K39/395 , A61P35/00
CPC分类号: C07K16/2878 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/75
-
公开(公告)号:EP3183267A1
公开(公告)日:2017-06-28
申请号:EP15753872.9
申请日:2015-08-17
发明人: WILLIAMS, Sybil, M. G. , LAFACE, Drake , FAYADAT-DILMAN, Laurence , RAGHUNATHAN, Gopalan , LIANG, Linda , SEGHEZZI, Wolfgang
IPC分类号: C07K16/28 , A61K39/395 , A61P37/02 , A61K39/00
CPC分类号: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
摘要翻译: 本发明涉及抗TIGIT抗体,以及这些抗体在治疗诸如癌症和传染病的疾病中的用途。
-
-
-
-
-
-
-
-
-